GERON CORP (GERN)
Health Care · NASDAQ
First-in-class telomerase inhibitor company with FDA-approved RYTELO for myelodysplastic syndromes, now expanding into myelofibrosis with Phase 3 clinical data pending.
What GERON CORP does
Geron is a commercial-stage biopharmaceutical company developing telomerase inhibitors to treat blood cancers. Its first-in-class product, RYTELO (imetelstat), was FDA-approved in June 2024 for lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia and received European Commission approval in March 2025. The company is expanding RYTELO's reach through commercial launch in the U.S. and selected EU markets, while advancing a Phase 3 trial (IMpactMF) evaluating imetelstat in myelofibrosis, a more advanced form of blood cancer.
Themes: ["Blood cancer / hematologic malignancies","Telomerase inhibitors","Myelodysplastic syndromes (MDS) treatment","Myelofibrosis treatment","Orphan/rare blood disorders"]
Fundamentals
- Price$1.56 as of 2026-07-09 close
- Market cap$1.0B as of 2026-07-10
- 1-year return+8.3% as of 2026-07-09 close
- Net margin-34.3% as of 2026-07-10
- Gross margin+97.3% as of 2026-07-10
- ROE-28.0% as of 2026-07-10
- Debt / equity1.09 as of 2026-07-10
- Revenue growth (YoY)+68.6% as of 2026-07-10
- Revenue CAGR (3y)-2.2% SEC XBRL
- Beta0.58 as of 2026-07-10
Key risks (from latest filing)
["Commercial execution risk: RYTELO is an early-stage commercialization with limited product revenue history; patient adoption in MDS may be slower than projected given physician unfamiliarity with telomerase inhibition mechanism and safety management requirements.","Clinical development risk: The Phase 3 IMpactMF trial in myelofibrosis is not expected to have interim OS data until H2 2026 and final analysis in H2 2028; failure or delays could limit revenue expansion beyond MDS.","Reimbursement and market access risk: European commercialization depends on securing favorable reimbursement and HTA outcomes; the company relies on third-party partners for EU commercialization and distribution, creating execution dependency."]
Competitors & peers
- Acceleron Pharma (part of Merck)
- Incyte (JAK inhibitors for MF)
- Celgene/Bristol Myers Squibb (lenalidomide, azacitadine for MDS)
- Otsuka/Astex (azacitadine)
- Vertex Pharmaceuticals (sickle cell and blood disorders)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.